Last reviewed · How we verify

NCT05416112: dp/dt

Non-invasive Left Ventricle Contractility dp/dt as Prognostic Marker in Chest Unit Patients

Status unknown Last updated 16 May 2023
What this trial tests

trial in Chest Pain in 500 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
31 May 2023
30 September 2023

Quick facts

Lead sponsorUniversity of Monastir
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 June 2022
Primary completion31 May 2023
Estimated completion30 September 2023
Sites1 location across Tunisia

Conditions studied

Sponsor

University of Monastir

Who can join

18 and older, any sex, with Chest Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ischemic heart disease is a major public health problem with high mortality rate despite the progress in management and the resources mobilized. The idea is that myocardial ischemia is generally associated with left ventricular dysfunction and, consequently, a possible alteration of the dp/dt index. As dp/dt could be assessed non-invasively by plethysmographic method, it is interesting to investigate its prognostic performance in patients with indifferentiate chest pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chest Pain

Currently open trials in the same condition.

Other University of Monastir trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05416112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing